Pharmaceuticals

HUIYU PHARMACEUTICAL

HUIYU PHARMACEUTICAL released FY2026 Q1 earnings on April 24 After-Market (BJT), actual revenue CNY 269.21 M, actual EPS CNY 0.05

HUIYU PHARMACEUTICAL FY2026 Q1 Earnings Release on April 25 After-Market (BJT)

HUIYU PHARMACEUTICAL to Release FY2025 Annual Earnings on April 25, 2026 Pre-Market (BJT)

HUIYU PHARMACEUTICAL released FY2025 Q4 earnings on February 27 Pre-Market (BJT), actual revenue CNY 256.39 M, actual EPS CNY 0.0655

HUIYU PHARMACEUTICAL released FY2025 annual earnings on February 27 Pre-Market (BJT), actual revenue CNY 998.14 M, actual EPS CNY -0.06

HUIYU PHARMACEUTICAL released FY2025 9 Months Earnings on October 29 After-Market (BJT), actual revenue CNY 741.75 M, actual EPS CNY -0.1192

HUIYU PHARMACEUTICAL released FY2025 Q3 earnings on October 29 After-Market (BJT), actual revenue CNY 288.63 M, actual EPS CNY 0.0711

HUIYU PHARMACEUTICAL FY2025 Q3 Earnings Release on October 30 After-Market BJT

HUIYU PHARMACEUTICAL released FY2025 Semi-Annual earnings on August 29 After-Market (BJT), actual revenue CNY 453.12 M, actual EPS CNY -0.19

HUIYU PHARMACEUTICAL released FY2025 Q2 earnings on August 29 After-Market (BJT), actual revenue CNY 214.07 M, actual EPS CNY -0.1303

HUIYU PHARMACEUTICAL FY2025 Semi-Annual Earnings Release on August 30, 2025 (BJT)

Huayi Pharmaceutical Publishes an International Patent Application

Huiyu Haiyue Completes First Clinical Trial Dosing of Innovative Drug

Huayu Pharmaceutical's Secretary Explains Company Strategy and R&D Projects

Huayu Pharmaceutical's Innovative Drug Injection HY0001a Completes First Dosing in Clinical Trial

Huayu Pharmaceutical Stock Rises 7.52% with Open Source Securities Issuing a Buy Rating Report

Huayu Pharmaceutical Reports Growth in 2024 and Expands into Innovative Drugs

Seacross Pharma Products Approved for Market in Germany and Saudi Arabia

Huiyu Pharmaceutical Responds to Investor Queries on Product Sales and Profitability

000001

301201

399001

603773

600707

399006

688553

002962

At the midday close on April 9, the SSE Index fell 0.73%, the Shenzhen Index dropped 0.31%, and the ChiNext decreased by 0.67%. The market opened lower and fluctuated in the morning, with computing power hardware stocks performing strongly; CDD, W-OLF TECH, WG Tech, and others hit their daily limits. Pharmaceutical stocks retreated, with CHENGDA PHARMA and HUIYU PHARMACEUTICAL falling by more than 10%. Overall, declining stocks outnumbered gainers, with approximately 4,400 stocks falling across the Shanghai, Shenzhen, and Beijing markets. Morning turnover reached 1.43 trillion yuan

Wallstreetcn

SSE Index

CHENGDA PHARMA

Shenzhen Index

WG Tech

ChiNext

W-OLF TECH

Midday Market Review on April 9: SSE Index Drops 0.73% in Half-Day, Computing Power Hardware Stocks Strengthen Against the Trend

HUIYU PHARMACEUTICAL plans to cooperate with professional institutions to establish a private equity fund, investing in the biomedical field, with a focus on key mid-to-late stage clinical projects. The initial scale of the fund is 400 million yuan, with HUIYU PHARMACEUTICAL as a limited partner subscribing 150 million yuan, accounting for 37.5%

36Kr

HUIYU PHARMACEUTICAL: Plans to collaborate with professional institutions to establish a private equity fund, primarily investing in the biomedical field

HUIYU PHARMACEUTICAL announced that its wholly-owned subsidiary Sichuan HUIYU Haiyue Pharmaceutical Technology Co., Ltd. participated in the national centralized drug procurement bidding. According to the announcement, one of the company's products, Mefenamic Acid Injection, is expected to win the bid at a price of 11.59 yuan, with the procurement period lasting until December 31, 2028

Zhitong

HUIYU PHARMACEUTICAL: The company participates in the national centralized drug procurement and intends to be selected

HUIYU PHARMACEUTICAL announced that the shares held by shareholder Huang Qianyi have been judicially frozen, totaling 5.7883 million shares, accounting for 21.27% of his shareholding and 1.37% of the company's total share capital. At the same time, Huang Qianyi has also been subject to a pending freeze of 6.0707 million shares, accounting for 22.30% of his shareholding and 1.43% of the company's total share capital. As of October 9, 2025, Huang Qianyi has a total of 27.2194 million shares judicially frozen, accounting for 100% of his shareholding and 6.43% of the company's total share capital; a total of 6.3507 million shares are pending freeze, accounting for 23.33% of his shareholding and 1.50% of the company's total share capital

HUIYU PHARMACEUTICAL: Shareholder Huang Qianyi's shares in the company have been judicially frozen and pending frozen

HUIYU PHARMACEUTICAL announced that its subsidiary Seacross Pharma (Europe) Ltd. has obtained marketing authorization for injectable paclitaxel (albumin-bound) from the regulatory authorities in the Netherlands, Ireland, Finland, and Sweden. The drug is indicated for the treatment of adult patients with metastatic breast cancer, metastatic pancreatic adenocarcinoma, and non-small cell lung cancer

HUIYU PHARMACEUTICAL: Injectable Paclitaxel (Albumin-Bound) Obtains Overseas Listing License

According to the Zhitong Finance APP, HUIYU PHARMACEUTICAL announced that the company's shareholder Ms. Wang Xiaopeng intends to reduce her holdings in the company by a total of no more than 12.708 million shares through centralized bidding and block trading, with the total reduction not exceeding 3% of the company's total shares

HUIYU PHARMACEUTICAL shareholder Wang Xiaopeng plans to reduce his holdings by no more than 3%

300705

002422

300111

688221

The chemical pharmaceutical sector rose in early trading, with SUNFLOWER hitting the daily limit of a 20cm increase, followed by gains in Froniter Biotechnologies, HUIYU PHARMACEUTICAL, JIUDIAN PHARMACEUTICAL, KELUN PHARMA, and Yuandong Biotech

JIUDIAN PHARMACEUTICAL

KELUN PHARMA

SUNFLOWER

Froniter Biotechnologies

The chemical pharmaceutical sector rose in early trading, with SUNFLOWER hitting the daily limit of a 20cm increase

HUIYU PHARMACEUTICAL and its subsidiaries Seacross Pharma (Europe) Ltd. and Seacross Pharmaceuticals Ltd. recently obtained overseas marketing approvals for multiple products, including injectable paclitaxel (albumin-bound), injectable cyclophosphamide, paclitaxel injection, injectable zoledronic acid concentrated solution, and injectable azacitidine, approved by the drug regulatory authorities of Denmark, Germany, Uzbekistan, and Bangladesh, respectively

HUIYU PHARMACEUTICAL and its subsidiaries have obtained overseas listing licenses for multiple products

HUIYU PHARMACEUTICAL announced that its shareholder, Shanghai Shuangsa Enterprise Management Consulting Co., Ltd., originally planned to reduce its holdings by no more than 12.6956 million shares through centralized bidding or block trading from June 3, 2025, to August 31, 2025, with a reduction ratio not exceeding 2.997%. As of the expiration of the planned period, no reduction has been implemented, with an actual reduction of 0 shares and a reduction ratio of 0%; it currently still holds 12.6956 million shares of the company, accounting for 2.997% of the company's total share capital

HUIYU PHARMACEUTICAL: Shanghai Shuangsa reduced holdings by 0% in March

HUIYU PHARMACEUTICAL(688553.SH)